Evidence map›Paper›PMID 35612280›Full record

ArticleJournal of the Royal Society, Interface2022

Critical roles for EGFR and EGFR-HER2 clusters in EGF binding of SW620 human carcinoma cells.

Adam J M Wollman, Charlotte Fournier, Isabel Llorente-Garcia, Oliver Harriman, Alex L Payne-Dwyer, Sviatlana Shashkova, Peng Zhou, Ta-Chun Liu, Djamila Ouaret, Jenny Wilding and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the Royal Society, Interface, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Adam J M WollmanDepartment of Physics, University of York, York, UK.
Charlotte FournierDepartment of Physics, Clarendon Laboratory, University of Oxford, Oxford OX1 3PU, UK.
Isabel Llorente-Garcia
Oliver HarrimanDepartment of Physics, Clarendon Laboratory, University of Oxford, Oxford OX1 3PU, UK.
Alex L Payne-DwyerDepartment of Physics, University of York, York, UK.ORCID 0000-0001-8802-352X
Sviatlana ShashkovaDepartment of Physics, University of York, York, UK.
Peng ZhouMembrane Cooperativity Unit, OIST, 1919 Tancha, Onna-son, Okinawa 904-0495, Japan.
Ta-Chun LiuMRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Djamila OuaretMRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Jenny WildingMRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Akihiro KusumiMembrane Cooperativity Unit, OIST, 1919 Tancha, Onna-son, Okinawa 904-0495, Japan.
Walter BodmerMRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Mark C LeakeDepartment of Physics, University of York, York, UK.ORCID 0000-0002-1715-1249
John Radcliffe Hospital · GBUniversity of York · GBOkinawa Institute of Science and Technology Graduate University · JPUniversity of Oxford · GB

Funding

Biotechnology and Biological Sciences Research Council BB/F021224/1Biotechnology and Biological Sciences Research Council BB/N006453/1Cancer Research UK C38302/A12278Medical Research Council MR/K01580X/1
6 · The paper itself

Abstract

Epidermal growth factor (EGF) signalling regulates normal epithelial and other cell growth, with EGF receptor (EGFR) overexpression reported in many cancers. However, the role of EGFR clusters in cancer and their dependence on EGF binding is unclear. We present novel single-molecule total internal reflection fluorescence microscopy of (i) EGF and EGFR in living cancer cells, (ii) the action of anti-cancer drugs that separately target EGFR and human EGFR2 (HER2) on these cells and (iii) EGFR-HER2 interactions. We selected human epithelial SW620 carcinoma cells for their low level of native EGFR expression, for stable transfection with fluorescent protein labelled EGFR, and imaged these using single-molecule localization microscopy to quantify receptor architectures and dynamics upon EGF binding. Prior to EGF binding, we observe pre-formed EGFR clusters. Unexpectedly, clusters likely contain both EGFR and HER2, consistent with co-diffusion of EGFR and HER2 observed in a different model CHO-K1 cell line, whose stoichiometry increases following EGF binding. We observe a mean EGFR : EGF stoichiometry of approximately 4 : 1 for plasma membrane-colocalized EGFR-EGF that we can explain using novel time-dependent kinetics modelling, indicating preferential ligand binding to monomers. Our results may inform future cancer drug developments.

Indexed as

Epidermal Growth FactorErbB ReceptorsCarcinomaCell Line, TumorColonic NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansPhosphorylationSignal TransductionEGFR protein, humanEpidermal Growth FactorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB Receptorscancerinhibitorsreceptorssingle moleculesuper-resolution

Identifiers

PMID35612280
PMCPMC9131850
OpenAlexW4281483806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.